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Extra-pulmonary small cell carcinomas (EPSCC) are rare malignancies. Like small cell lung cancer (SCLC), they
are aggressive malignancies with dismal prognosis. We here report a case of a middle-aged man who presented
with odynophagia and cervical lymphadenopathy. Diagnostic workup confirmed the diagnosis of locallyadvanced p16-positive oropharyngeal cancer (OPC) with a surprising histology of small cell cancer, suggesting
a human papilloma virus (HPV)-related oropharyngeal cancer with small cell differentiation. HPV oropharynx
infection is a well-known risk factor for squamous cell carcinoma of the oropharynx, but it is unknown if it may
increase the risk of other OPC histology.

Introduction
Small cell carcinoma (SmCC) is an aggressive malignancy that occurs
mainly in the lungs secondary to cigarette smoking. It is defined by
World Health Organization as poorly differentiated neuroendocrine tu
mors, and marked by the presence of neurosecretory granules in its
tumor cells. Though rare, extra-pulmonary small cell carcinomas
(EPSCCs) have also been reported at a rate of 5.8% of SmCC cases [1].
The most frequent EPSCCs involve the gastrointestinal and genitouri
nary systems, including the esophagus, stomach, colon, rectum, anus,
gallbladder, cervix, vagina, prostate, and bladder. EPSCC has been
described in nearly every organ system [2], with head and neck
constituting 11–21% of all EPSCC [1]. Oropharyngeal presentation of
SmCCs has been reported with an incidence rate of 0.003 per 100,000
[3]. Risk factors like tobacco and alcohol have been linked as possible
etiologies for EPSCC [4]. Also, contrary to p16+ oropharyngeal squa
mous cell carcinoma, which are proven to be related to human papil
lomavirus (HPV) oropharyngeal infection and to have better prognosis
in comparison to other squamous cell cancers of the same region [5],
p16+ oropharyngeal (OP) SmCCs may or may not have a cause-effect
relationship to HPV, and the aggressive clinical behavior of SmCC
may overwhelm the prognosis benefit of HPV related tumors. The role of
HPV on the pathogenesis of SmCC is not clear [6]. Due to the rare
incidence of this cancer, more data is needed to better understand the
presentation, pathology, immunohistochemistry and treatment modal
ities; and thus, we present a rare case of SmCC on the epiglottis.
Case presentation
A 52-year-old man with minimal smoking history presented with
odynophagia and a palpable neck mass. Physical examination revealed a
polyploid mass in the right oropharynx and enlarged lymph nodes at the
right anterior cervical region. A contrast-enhanced CT of the neck
showed a right-sided level 2/3 cervical lymphadenopathy composed of
conglomerated masses with the largest being 2.7 cm with ill-defined
margins concerning for extracapsular spread (N3b), and a 2.9 cm mass

at the right base of the tongue infiltrating the proximal lingual surface of
the epiglottis (T3) (Fig. 1A). Further imaging showed no other lesions in
the brain, head and neck, chest, or abdomen (cT3N1M0, clinical Stage
III). Similarly, PET scan and MRI of the brain did not reveal any distant
metastases.
The fine needle aspiration of the neck mass was positive for malig
nant cells. A follow up core biopsy demonstrated nests and sheets of
round to oval small neoplastic cells (Fig. 2A). The neoplastic cells had
indistinct cell borders, scant cytoplasm, hyperchromatic nuclei, fine
granular (salt and pepper) chromatin with no distinct nucleoli. Nuclear
modeling and smudging with scattered brisk mitotic activity were also
evident (Fig. 2B). The neoplastic cells were immunoreactive to TTF-1
(Fig. 2C), Synaptophysin (Fig. 2D) and p16 (Fig. 2E). They were nonimmunoreactive to chromogranin, p40, p63 and Napsin. The
morphology and immune-profile was consistent with the diagnosis of
metastatic p16 positive SmCC.
The patient was diagnosed with locally-advanced SmCC of the
oropharynx (T3N3b; stage IVB AJCC 8th edition) and treated with
concurrent chemoradiation utilizing cisplatin and etoposide and defin
itive radiation dose of 6600 cGy/33 fractions, followed by 2 cycles of
chemotherapy to complete a course of 4 cycles of systemic therapy.
Repeat imaging after chemoradiation and 4 cycles of chemotherapy
showed complete response with no evidence of disease (Fig. 1B). The
patient continues to be in remission for 14 months.
Discussion
This is a very rare case of SmCC of the oropharynx. As in our case, the
classic and distinctive histologic findings on hematoxylin and eosin are
sufficient to make the diagnosis. In support of the diagnosis, synapto
physin and chromogranin were positive. Due to the lack of specific
treatment protocols for this condition, the most reasonable approach
was to adapt a plan similar to that of lung SmCC [7]. Since chemo
radiation has been reported to yield the best 5-year disease-specific
survival as compared to other modalities (31% versus 13%) [1], che
moradiation was warranted in treating this patient. This patient
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Fig. 1. (A) shows the pre-treatment PET scan and (B) demonstrates the complete response seen post-treatment.

Fig. 2. The Hematoxylin and Eosin (H&E) histology sections of the core biopsy demonstrate nests and sheets of round to oval small neoplastic cells (A). The
neoplastic cells have indistinct cell borders, scant cytoplasm, hyperchromatic nuclei, fine granular (salt and paper) chromatin with no distinct nucleoli. Nuclear
molding and smudging with scattered brisk mitotic activity are also evident (B). The neoplastic cells are immunoreactive to TTF-1 (C), Synaptophysin (D) and P16
(E). They are non-immunoreactive to chromogranin, P40, P63 and Napsin. The morphology and the immunoprofile is consistent with the diagnosis of metastatic P16
positive small cell carcinoma.

received treatment mirroring the current paradigm for limited stage
small cell lung cancer leading to a complete response after 4 cycles. One
case series used neoadjuvant chemotherapy for varying number of cy
cles followed by chemoradiation [1].
The association between HPV and oropharyngeal squamous cell
carcinoma (p16-positive OPCs) is well established and so is the HPV
status as an independent prognostic factor [8,9]. On the other hand, p16
positivity in SmCC of the oropharynx might not carry a similar favorable
prognostic value. In fact, p16 positivity might not be reflective of HPV

infection. Alos et al described a series of 14 SmCC cases of the head and
neck; all of which were strongly positive for p-16 but negative for HPV
by in situ hybridization and PCR. Eleven of them had loss of protein
retinoblastoma 1 (Rb1) [10]. However, Kraft et al reported 8 cases of
oropharyngeal SmCC; of which 7 overexpressed p16 and 6 had a
confirmed HPV infection by in situ hybridization and/or PCR [11].
While loss of Rb1 is almost ubiquitous in SCLC [12–13], the role of this
in the tumorigenesis of EPSCC is not clear.
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We report a rare case of extrapulmonary small cell carcinoma orig
inating from the oropharynx. A multidisciplinary approach was essential
for diagnosing and treating this patient. He achieved a complete
response with definitive chemoradiation and a total of 4 cycles of sys
temic chemotherapy. The role of p16 positivity and correlation with
HPV infection remains to be further studied.
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